(Q35570944)

8 August 2017

1 reference

title

New drugs for the treatment of hypercholesterolaemia (English)

1 reference

8 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

26 March 2024

author name string

Pedro Iglesias

1

1 reference

8 August 2017

Juan J. Díez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14585054

26 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/13543784.12.11.1777

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Expert Opinion on Investigational Drugs

26 March 2024

published in

1 reference

8 August 2017

volume

12

1 reference

8 August 2017

issue

11

1 reference

8 August 2017

page(s)

1777-1789

1 reference

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

New advances in lipid-modifying therapies for reducing cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The future direction of cholesterol-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

New cholesterol guidelines, new treatment challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

New lipid-modifying therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

A proposed model for the assembly of chylomicrons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Rosuvastatin for the treatment of patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Rosuvastatin--a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

NK-104: a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Plant sterol and stanol margarines and health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Orlistat inhibits dietary cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Characterization of two human genes encoding acyl coenzyme A:cholesterol acyltransferase-related enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Colesevelam hydrochloride: a novel bile acid-binding resin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Colesevelam: a new bile acid sequestrant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

Inhibitors of Cholesterol Biosynthesis Increase Hepatic Low-Density Lipoprotein Receptor Protein Degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.11.1777

21 January 2018

Cholesterol absorption.

33

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers

26 March 2024

35

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

26 March 2024

39

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor

26 March 2024

58

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection

26 March 2024

59

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group

26 March 2024

60

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Effects of partial replacement of dietary fat by olestra on dietary cholesterol absorption in man

26 March 2024

67

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

26 March 2024

Ezetimibe

72

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Clinical Pharmacology & Therapeutics

26 March 2024

77

67

152

ZHU Y

2000

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

CI-1011 lowers lipoprotein(a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys

26 March 2024

88

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Colesevelam hydrochloride.

26 March 2024

102

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

26 March 2024

104

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent

26 March 2024

110

1 reference

https://api.crossref.org/works/10.1517/13543784.12.11.1777

26 March 2024

Identifiers

1 reference

8 August 2017

1 reference